SOLICITATION NOTICE
A -- Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership
- Notice Date
- 2/25/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- RFA-DA-11-015
- Archive Date
- 6/15/2011
- Point of Contact
- Medications Initiative for Tobacco Dependence, Phone: 301-443-9800
- E-Mail Address
-
NIDAMedTDWG@mail.nih.gov
(NIDAMedTDWG@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS NOT A CONTRACT RFP. THIS IS A GRANT FUNDING OPPORTUNITY. Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership. See announcement (and link) below for complete information: (PDP)(UH2/UH3) http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-11-015.html RFA-DA-11-015 Letter of Intent Due Date: March 26, 2011 Application Due Date: April 26, 2011 by 5:00PM local time of applicant organization FOA Purpose: The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from qualified non-profit, private and academic researchers/organizations to participate in the planning and execution of a new public-private partnership (PPP). The purpose of a one-year planning phase (UH2) is to provide support for the systematic study directed toward fuller scientific understanding of the opportunities in the area of drug discovery and development for tobacco dependence, with the ultimate goal of establishing a PPP, specifically, a Product Development Partnership (PDP). The mission of the PDP is to develop safe and effective medications for the treatment of tobacco dependence, including aids for smoking cessation. Phase two (UH3) funding will be utilized to support the implementation and execution phase of the PDP, with one selected cooperative agreement recipient assuming the role of the PDP's Managing Partner. In this subsequent phase, the PDP will conduct a wide array of research and development (R&D) projects aimed at the fulfillment of regulatory requirements for approval for marketing in the US. See announcement for complete information Please send inquiries to Medications Initiative for Tobacco Dependence: NIDAMedTDWG@mail.nih.gov or call 301-443-9800
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/RFA-DA-11-015 /listing.html)
- Record
- SN02388138-W 20110227/110225234540-8700557f43642c1e69ed2805a7aeae13 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |